Palatin Technologies, Inc. (PTN)
PTNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$6.23
-0.2630 (-4.05%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $11.10m
- P/E
- –
- EPS, last 4 quarters
- $-0.0800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.51 to $31.00
- Average volume
- –
- Previous close
- $6.49
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $12.00, +92.6% from here
Earnings
next estimate $-0.3200Next report
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $8.85m | $116.0k | $3.92m | $301.0k |
| Gross profit | $8.85m | $116.0k | $3.92m | $301.0k |
| Operating income | $4.66m | -$7.33m | -$1.58m | -$4.42m |
| Net income | $4.68m | -$7.26m | -$1.43m | -$4.36m |
Last four quarters: revenue $13.19m, margin -63.5%, free cash flow –
News
8 latest- Palatin (PTN) Q4 2026 Earnings Call TranscriptThe Motley Fool · Sep 29, 2026
- This High-Flying Growth Stock Is Hiding in Plain SightThe Motley Fool · Feb 2, 2026
- Palatin Achieves Milestone Payment Of $6.5 Mln Under Boehringer Ingelheim Collaboration RTTNews · Sep 22, 2025
- Insider Purchase: Executive VP and CFO/COO of $PTN Buys 1,500 SharesQuiver Quantitative · Jun 17, 2025
- Palatin Technologies Q1 Net Loss Narrows On Lower Expenses RTTNews · May 14, 2025
- Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 RTTNews · May 9, 2025
- Palatin Prices $11.5 Mln Public Offering RTTNews · May 7, 2025
- Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development RTTNews · May 7, 2025
The company
Palatin is a biopharmaceutical company developing first-in-class medicines based on peptide and small-molecule compounds that modulate the activity of the melanocortin receptor system. Palatin's principal strategic development focus is advancing selective MC4R agonists for rare obesity disorders, while utilizing collaborations, licensing arrangements and strategic partnerships to advance other MCR-based programs and generate potential milestone and royalty economics.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- palatin.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.